KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Finished Goods (2018 - 2021)

BioNTech SE's Finished Goods history spans 4 years, with the latest figure at $194.1 million for Q4 2021.

  • On a quarterly basis, Finished Goods rose 40605.68% to $194.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $194.1 million, a 40605.68% increase, with the full-year FY2021 number at $194.1 million, up 40605.68% from a year prior.
  • Finished Goods hit $194.1 million in Q4 2021 for BioNTech SE, up from $96.7 million in the prior quarter.
  • Over the last five years, Finished Goods for BNTX hit a ceiling of $194.1 million in Q4 2021 and a floor of $476915.9 in Q4 2020.
  • Historically, Finished Goods has averaged $58.7 million across 4 years, with a median of $1.4 million in 2018.
  • Biggest five-year swings in Finished Goods: tumbled 50.25% in 2019 and later soared 40605.68% in 2021.
  • Tracing BNTX's Finished Goods over 4 years: stood at $1.4 million in 2018, then tumbled by 50.25% to $700659.9 in 2019, then plummeted by 31.93% to $476915.9 in 2020, then soared by 40605.68% to $194.1 million in 2021.
  • Business Quant data shows Finished Goods for BNTX at $194.1 million in Q4 2021, $96.7 million in Q2 2021, and $476915.9 in Q4 2020.